Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
MacroGenics announced that Gilead Sciences has exercised its option under their 2022 collaboration agreement to exclusively license a preclinical bispecific program targeting solid tumors. This action triggers a $10 million milestone payment to MacroGenics. The collaboration includes one clinical-stage and two preclinical bispecific programs, with …
GrowGeneration Corp., a leading supplier in controlled environment agriculture and commercial cultivation, reported a 5.5% year-over-year sales increase to $43.2 million in Q2 2026 alongside an improved net loss and positive Adjusted EBITDA. The company enhanced its proprietary brand penetration to nearly 40% of cultivation sales and strengthened i…
Pliant Therapeutics, a clinical-stage biotech focused on integrin therapeutics, provided a corporate update highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095 in ICI-refractory solid tumors. The company appointed experienced oncology drug development leaders to its board, showcased promising biomarker data indicating tumor …
Spectral AI announced its Q2 2026 financial results, highlighting FDA clearance for its DeepView® System for burn indication and a strong cash position of $14 million. The company received $31.7 million in BARDA funding and is positioned to commence first commercial sales by the end of 2026. Despite a net loss of $4.2 million for the quarter, the c…
Codexis, Inc. reported Q2 2026 revenue of $14.9 million and reiterated full-year guidance. The company highlighted advances in its ECO Synthesis® Manufacturing Platform enabling enzyme-driven stereoisomer control of siRNA, strengthening its position in RNA therapeutics manufacturing. A successful $25 million equity raise enhanced its cash position …
Bolt Biotherapeutics announced its second quarter 2026 financial results and provided an update on its lead candidate BDC-4182, a Boltbody ISAC targeting claudin 18.2 for gastric and gastroesophageal cancers. The Phase 1/2 clinical trial is ongoing with patients in Cohort 4 and initial clinical data are expected in Q3 2026. The company had $18.1 mi…
LENZ Therapeutics reported $5.5 million revenue in Q2 2026 driven by VIZZ (aceclidine ophthalmic solution) sales and global licensing agreements. Strong patient refill rates and the launch of a telehealth prescribing channel in July 2026 are early indicators of sustained growth. The company expanded international partnerships and regulatory submiss…
Snail, Inc. announced its Q2 2026 financial results showing a slight decrease in net revenues but a significant improvement in net loss. The company expanded its ARK franchise with new DLCs, saw positive early engagement with the Bellwright console launch, and showcased progress on several upcoming AAA games. Additionally, Snail introduced an AI ga…
Inuvo, Inc. announced the retirement of its long-serving CFO Wallace Ruiz after 16 years, with Derric Ciccone appointed as President and CFO and Aleesha Parris promoted to Chief Accounting Officer. The leadership changes aim to support Inuvo's continued scaling and transformation in AI-driven advertising technology.
Black Rock Coffee Bar, Inc. announced strong second quarter 2026 results, featuring a 25.0% year-over-year increase in total revenue to $63.0 million and a 4.2% same store sales growth. The company opened 10 new stores during the quarter, expanding its footprint to 200 locations systemwide. Income from operations grew to $4.1 million, and net incom…
Canterbury Park Holding Corporation reported a 3.2% increase in net revenues to $16.2 million for Q2 2026 and a 29.3% increase in adjusted EBITDA to $2.6 million, reflecting growth across Casino, Pari-mutuel, and Food and Beverage operations. Despite a net loss due to an impairment charge linked to prior horserace purse overpayments, the company sh…
Kyverna Therapeutics reported Q2 2026 financial results and significant clinical and regulatory progress for its lead CAR T-cell therapy candidate, miv-cel, targeting neurologic autoimmune diseases. The FDA granted RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis, highlighting promising clinical data. The company …
Erasca, Inc. announced encouraging updated clinical data for its ERAS-0015 candidate showing promising efficacy and tolerability in KRAS G12X pancreatic and lung cancers. The company raised $632 million in a recent upsized public offering to advance multiple registration-enabling trials and strengthen its balance sheet. Several key clinical milesto…
Maze Therapeutics announced its Q2 2026 financial results alongside clinical updates on its Phase 2 programs targeting APOL1-mediated kidney disease and phenylketonuria. Enrollment in multiple Phase 2 trials is progressing on schedule, with important data expected in late 2026 and 2027. The company holds a strong cash position of nearly $495 millio…
Aquestive Therapeutics reported a Q2 2026 revenue increase driven by manufacturing and royalties and reaffirmed plans to resubmit its Anaphylm (dibutepinephrine) NDA to the FDA in Q3 2026 following successful human factors and pharmacokinetic studies. The company continues to advance its epinephrine AdrenaVerse platform, including AQST-108 for derm…
Leonardo DRS demonstrated that its SGT STOUT M-SHORAD Mission Equipment Package can effectively defeat smaller Group 1-2 unmanned aerial systems through software updates without hardware changes, highlighting its modular and upgradeable architecture. This marks a significant advancement in scalable, modern air defense capabilities, emphasizing rapi…
Belite Bio announced FDA acceptance and Priority Review of its New Drug Application for tinlarebant, a novel oral therapy intended to treat Stargardt Disease Type 1 (STGD1), a rare inherited retinal disease. The NDA submission is supported by positive Phase 3 DRAGON trial results demonstrating a 35.7% reduction in atrophic retinal lesion growth rat…
Inhibikase Therapeutics announced its Q2 2026 financial results, highlighting significant progress in its Phase 3 IMPROVE-PAH clinical trial for IKT-001, a novel oral treatment for Pulmonary Arterial Hypertension (PAH). The company secured regulatory approvals in 26 countries, initiated 43 clinical sites globally, and obtained Orphan Drug Designati…
Taysha Gene Therapies reported Q2 2026 financial results and corporate updates including completed dosing in its pivotal REVEAL and ASPIRE trials for TSHA-102 gene therapy targeting Rett syndrome. The therapy showed a favorable safety profile and promising longer-term functional benefits. The company has advanced commercial and manufacturing readin…
Xcel Brands, a media and consumer products company, announced it will report its Q2 2026 financial results on August 13, 2026, followed by an earnings call on August 14. The company focuses on branded apparel, accessories, and social commerce, owning several lifestyle brands and utilizing diverse sales channels including live streaming and interact…
Lyft is not the global behemoth Uber is, but it has carved an economically viable niche in North America. With free cash flow of roughly $1.12B, a market cap near $7.0B and a P/E around 2.3, Lyft looks attractively priced for a mid-term tactical long. Trade plan: enter $17.55, stop $15.00, target $22.00 over a mid term (45 trading days).
Northrop Grumman has revealed Raid Hunter, a 50mm gun-centered air defense solution built to protect installations from cruise missiles, drone swarms and similar aerial threats. The system pairs Chain Gun mechanics, precision-guided 50mm rounds and a networked controller to deliver sustained, rapid fire from deep magazines. Designed for rapid movem…
This week two Mexican energy-related issuers requested regulatory clearances for capital market transactions spanning domestic and international markets. Esentia Energy Development confidentially updated its share registration to permit a potential mixed global stock offering, including American Depository Shares in foreign markets. CFECapital, man…
Norway’s $2.3 trillion sovereign wealth fund reported owning a 0.05% stake in SpaceX valued at $1.22 billion on June 30, according to an updated holdings list. The position is a comparatively small part of the fund’s technology exposure within a portfolio that spans roughly 7,200 companies and includes allocations to property and renewable energy.
Chicago Board of Trade soybean futures fell on Tuesday as market participants adjusted positions ahead of a U.S. Department of Agriculture supply and demand report due Wednesday. Analysts noted recent rainfall and cooler temperatures have aided recovery of the U.S. Midwest soybean crop after July's heat and dryness. A Reuters survey expects the USD…
